UBS Reaffirms Their Buy Rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD)
UBS analyst Marcus Curley maintained a Buy rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD – Research Report) today. The company's shares opened today at A$37.29.
Protect Your Portfolio Against Market Uncertainty
Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
According to TipRanks, Curley is an analyst with an average return of -14.0% and a 41.10% success rate.
In addition to UBS, Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh also received a Buy from Morgan Stanley's David Bailey in a report issued on April 28. However, on April 24, Wilsons maintained a Hold rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (ASX: RMD).
Based on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of A$1.29 billion and a net profit of A$365.04 million. In comparison, last year the company earned a revenue of A$1.2 billion and had a net profit of A$300.49 million
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
38 minutes ago
- Yahoo
UBS Capital Requirements Rise Following Switzerland's Proposal
Switzerland's Federal Department of Finance ('FDF') has proposed stricter rules for UBS Group AG UBS following its takeover of Credit Suisse. The move has been attempted to reduce the risks of another Credit Suisse-style Swiss government has proposed that UBS should fully capitalize its foreign subsidiaries, up from the current 60% threshold. This will require UBS to increase its common equity tier-one capital by up to $26 bank will be allowed to reduce its Additional Tier 1 (AT1) bond holdings by $8 billion. Still, this will result in a net increase of $18 billion in FDF stated, 'The Credit Suisse crisis made it clear that the Swiss parent bank's capital base was insufficient. The implementation of the package of measures is intended to substantially reduce the likelihood that another systemically important bank in Switzerland will get into a severe crisis, and that emergency measures by the state will be required.'Per the FDF, this estimate assumed no change in UBS's balance sheet size, risk-weighted assets or its potential use of mitigation said it 'strongly disagrees with the extreme increase in capital requirements that has been proposed. These changes would result in capital requirements that are neither proportionate nor internationally aligned.'Notably, the 'too big to fail' proposals (still subject to parliamentary approval) have come after the Swiss financial regulator granted capital relief to Credit Suisse in 2017, allowing the bank to inflate the value of its foreign the new capital proposals will be put out for consultation before being submitted to the the FDF, the proposed reforms will not become law before 2028, and UBS will be given a six to eight-year transition period to implement the changes once the legislation comes into force. UBS took over its rival Credit Suisse in a state-sponsored rescue in then, UBS has been facing challenges and legal claims, which is increasing costs. Last month, UBS agreed to pay $511 million to resolve a tax probe by the U.S. Department of Justice against Credit Suisse for preparing false income tax returns and tax UBS is on track to substantially complete the integration of Credit Suisse by the end of 2026 and, hence, achieve the targeted cost the first quarter of 2025, UBS completed consolidating its branch network in Switzerland, merging 95 branches since the July 2024 merger with Credit Suisse. The company is initiating its Swiss business migrations and aims to complete the migrations by the first quarter of the first quarter of 2025, UBS realized an additional $0.9 billion in gross cost savings. Cumulative gross cost savings at the end of the first quarter of 2025 amounted to $8.4 billion compared with the 2022 combined cost base of UBS and Credit Suisse. This represents around 65% of its ambition to deliver $13 billion in annualized exit rate gross cost savings by the end of 2026. Over the past six months, UBS shares have gained 6.1% compared with the industry's growth of 23.1%. Image Source: Zacks Investment Research Currently, UBS carries a Zacks Rank #3 (Hold). A couple of better-ranked peer stocks are Deutsche Bank Aktiengesellschaft DB and Mitsubishi UFJ Financial Group, Inc. MUFG, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today's Zacks #1 Rank stocks estimates for DB for the current year have been revised 4.2% upward over the past 60 days. Over the past six months, DB shares have soared 57.7%.MUFG's current fiscal-year earnings estimates have been revised 4.6% higher over the past 60 days. MUFG shares have gained 16.5% over the past six months. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Deutsche Bank Aktiengesellschaft (DB) : Free Stock Analysis Report UBS Group AG (UBS) : Free Stock Analysis Report Mitsubishi UFJ Financial Group, Inc. (MUFG) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Business Insider
an hour ago
- Business Insider
IPG Photonics management to meet virtually with Seaport Research
Virtual Meeting to be held on June 16 hosted by Seaport Research. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Yahoo
an hour ago
- Yahoo
ASX Penny Stocks: Frontier Digital Ventures And 2 Other Promising Picks
As the Australian market eases back into action after a brief hiatus, investors are keenly observing developments both locally and internationally, with trade talks and economic reports shaping the landscape. Despite being an older term, "penny stocks" continue to hold relevance for those looking to uncover growth opportunities in smaller or newer companies. With strong financial foundations, these stocks can offer attractive potential returns at lower price points, making them intriguing options for discerning investors. Name Share Price Market Cap Financial Health Rating EZZ Life Science Holdings (ASX:EZZ) A$1.50 A$70.76M ★★★★★★ GTN (ASX:GTN) A$0.65 A$124.05M ★★★★★★ IVE Group (ASX:IGL) A$2.57 A$396.25M ★★★★★☆ Southern Cross Electrical Engineering (ASX:SXE) A$1.67 A$441.56M ★★★★★★ Tasmea (ASX:TEA) A$3.08 A$725.72M ★★★★★☆ Regal Partners (ASX:RPL) A$2.25 A$756.37M ★★★★★★ Accent Group (ASX:AX1) A$1.845 A$1.11B ★★★★☆☆ Lindsay Australia (ASX:LAU) A$0.71 A$225.19M ★★★★☆☆ Bisalloy Steel Group (ASX:BIS) A$3.37 A$159.91M ★★★★★★ CTI Logistics (ASX:CLX) A$1.815 A$146.19M ★★★★☆☆ Click here to see the full list of 1,003 stocks from our ASX Penny Stocks screener. Below we spotlight a couple of our favorites from our exclusive screener. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Frontier Digital Ventures Limited is a private equity firm focused on investing in and developing online classifieds businesses in emerging markets, with a market cap of A$99.75 million. Operations: Frontier Digital Ventures generates revenue from its online classifieds businesses across various regions, with notable contributions from Infocasas (A$19.43 million), Fincaraiz (A$14.14 million), Encuentra24 (A$11.65 million), and Avito (A$7.66 million). Market Cap: A$99.75M Frontier Digital Ventures has a market cap of A$99.75 million and focuses on online classifieds in emerging markets, generating significant revenue from businesses like Infocasas and Fincaraiz. Despite being unprofitable, it maintains a strong cash position with short-term assets exceeding liabilities, allowing for over a year of runway based on current free cash flow. The company has reduced its debt-to-equity ratio significantly over five years and holds more cash than total debt. Recent board changes include the appointment of Patrick Grove as Director, which may influence strategic direction amidst high share price volatility. Jump into the full analysis health report here for a deeper understanding of Frontier Digital Ventures. Gain insights into Frontier Digital Ventures' future direction by reviewing our growth report. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Imugene Limited is a clinical stage immuno-oncology company in Australia that develops immunotherapies aimed at activating the immune system to treat and eradicate cancerous tumors, with a market cap of A$119.47 million. Operations: Imugene generates its revenue from the research, development, and commercialisation of health technologies, with reported earnings of -A$1.84 million. Market Cap: A$119.47M Imugene Limited, with a market cap of A$119.47 million, is a clinical-stage immuno-oncology company that remains pre-revenue, generating less than US$1 million. Despite being unprofitable and not expected to reach profitability in the next three years, Imugene's short-term assets significantly exceed both its short and long-term liabilities. The company has more cash than debt but faces a limited cash runway of 3-4 months based on past free cash flow estimates. Recent developments include its addition to the S&P/ASX Emerging Companies Index and presentations at industry conferences by CEO Leslie Chong. Dive into the specifics of Imugene here with our thorough balance sheet health report. Review our growth performance report to gain insights into Imugene's future. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Kingsgate Consolidated Limited is involved in the exploration, development, and mining of gold and silver mineral properties with a market capitalization of A$560.50 million. Operations: The company's revenue is primarily generated from its Chatree segment, which reported A$210.69 million. Market Cap: A$560.5M Kingsgate Consolidated, with a market cap of A$560.50 million, demonstrates strong financial performance in the penny stock category. The company has shown impressive earnings growth of 1203% over the past year, significantly outpacing industry averages. Its debt management is robust, with operating cash flow covering 69% of its debt and EBIT covering interest payments 17.2 times over. Recent announcements include a share buyback program aimed at enhancing shareholder value as part of its capital management strategy. However, while short-term liabilities are covered by assets, long-term liabilities remain uncovered by current short-term assets. Unlock comprehensive insights into our analysis of Kingsgate Consolidated stock in this financial health report. Explore Kingsgate Consolidated's analyst forecasts in our growth report. Unlock our comprehensive list of 1,003 ASX Penny Stocks by clicking here. Seeking Other Investments? We've found 17 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:FDV ASX:IMU and ASX:KCN. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
